title: Randomized phase II trial evaluation of erectile function after attempted unilateral cavernous nerve-sparing retropubic radical prostatectomy with versus without unilateral sural nerve grafting for clinically localized prostate cancer.
abstract: BACKGROUND
  Nonrandomized studies of unilateral nerve-sparing (UNS) radical prostatectomy (RP) have reported improved recovery of erectile function if the sacrificed cavernous nerve is reconstructed with a sural nerve graft (SNG).
  
  
  OBJECTIVE
  To determine whether UNS RP plus SNG results in a 50% relative increase in potency at 2 yr compared to UNS RP alone.
  
  
  METHODS
  The study enrolled patients from October 2001-May 2006 from a single academic center and was randomized, open label. Participants were men with localized prostate cancer recommended for UNS RP, less than 66 yr old, normal baseline erectile function, and willing to participate in early erectile dysfunction (ED) therapy. Patients were followed up to 2 yr.
  
  
  METHODS
  Patients underwent UNS RP and ED therapy starting at 6 wk: oral prostaglandin type-5 (PDE5) inhibitor, vacuum erection device (VED), and intracavernosal injection therapy. In the SNG group, a plastic surgeon performed the procedure at the time of RP.
  
  
  METHODS
  The ability to have an erection suitable for intercourse with or without a PDE5 inhibitor at 2 yr. The hypothesis was that SNG would result in a 60% potency rate compared to 40% for controls (80% power, 5% two-way significance).
  
  
  CONCLUSIONS
  The trial planned to enroll 200 patients, but an interim analysis at 107 patients met criteria for futility and the trial was closed. For patients completing the protocol to 2 yr, potency was recovered in 32 of 45 (71%) of SNG and 14 of 21 (67%) of controls (p=0.777). By intent-to-treat analysis, potency recovered in 32 of 66 (48.5%) of SNG and 14 of 41 (34%) of controls (p=0.271). No differences were seen in time to potency or quality of life scores for ED and urinary function. Limitations included slower-than-expected accrual and poor compliance with ED therapy: <65% for VED and <40% for injections.
  
  
  CONCLUSIONS
  The addition of SNG to a UNS RP did not improve potency at 2 yr following surgery.
  
  
  BACKGROUND
  ClinicalTrials.gov, Identifier: NCT00080808, http://www.clinicaltrials.gov/ct2/show/NCT00080808?term=NCT00080808&rank=1.
authors.affiliation: Department of Urology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA. johndavis@mdanderson.org
authors.forename: John W
authors.initials: JW
authors.lastname: Davis
authors.forename: David W
authors.initials: DW
authors.lastname: Chang
authors.forename: Pierre
authors.initials: P
authors.lastname: Chevray
authors.forename: Run
authors.initials: R
authors.lastname: Wang
authors.forename: Yu
authors.initials: Y
authors.lastname: Shen
authors.forename: Sijin
authors.initials: S
authors.lastname: Wen
authors.forename: Curtis A
authors.initials: CA
authors.lastname: Pettaway
authors.forename: Louis L
authors.initials: LL
authors.lastname: Pisters
authors.forename: David A
authors.initials: DA
authors.lastname: Swanson
authors.forename: Lydia T
authors.initials: LT
authors.lastname: Madsen
authors.forename: Nelda
authors.initials: N
authors.lastname: Huber
authors.forename: Patricia
authors.initials: P
authors.lastname: Troncoso
authors.forename: R Joseph
authors.initials: RJ
authors.lastname: Babaian
authors.forename: Christopher G
authors.initials: CG
authors.lastname: Wood
mesh_terms: D007172:Erectile Dysfunction / Q000209:etiology / Q000517:prevention & control*; D005500:Follow-Up Studies; D006085:Graft Survival; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009416:Nerve Regeneration / Q000502:physiology; D010410:Penile Erection / Q000502:physiology*; D010413:Penis / Q000294:innervation; D011183:Postoperative Complications / Q000503:physiopathology; D011336:Probability; D011468:Prostatectomy / Q000009:adverse effects / Q000379:methods*; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000601:surgery*; D018570:Risk Assessment; D013497:Sural Nerve / Q000637:transplantation*; D013997:Time Factors; D016896:Treatment Outcome; D014554:Urination / Q000502:physiology
references.citation: J Urol. 2007 Jul;178(1):212-6; discussion 216
references.pmid: 17499797
references.citation: Eur Urol. 2006 Oct;50(4):711-8; discussion 718-20
references.pmid: 16846679
references.citation: BJU Int. 2007 Nov;100(5):1107-9
references.pmid: 17578520
references.citation: Urology. 2004 Jun;63(6):1122-7
references.pmid: 15183964
references.citation: Urology. 2006 Dec;68(6):1290-4
references.pmid: 17141842
references.citation: Med Care. 1998 Jul;36(7):1002-12
references.pmid: 9674618
references.citation: J Urol. 1999 Jan;161(1):188-92
references.pmid: 10037395
references.citation: Plast Reconstr Surg. 2003 Mar;111(3):1174-81
references.pmid: 12621188
references.citation: Urology. 2001 Mar;57(3):491-4
references.pmid: 11248626
references.citation: J Urol. 2007 Feb;177(2):664-8
references.pmid: 17222654
references.citation: J Urol. 1996 Nov;156(5):1707-13
references.pmid: 8863576
references.citation: Urology. 2001 Dec;58(6):983-7
references.pmid: 11744473
references.citation: BJU Int. 2005 Jun;95(9):1267-71
references.pmid: 15892814
references.citation: Biometrics. 1979 Sep;35(3):549-56
references.pmid: 497341
references.citation: Urol Clin North Am. 2001 Aug;28(3):535-43
references.pmid: 11590812
references.citation: J Urol. 2006 Mar;175(3 Pt 1):907-12
references.pmid: 16469577
references.citation: Urology. 1997 Jun;49(6):822-30
references.pmid: 9187685